J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil
{"title":"尼达尼布和吡非尼酮治疗特发性肺纤维化的有效性和安全性","authors":"J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil","doi":"10.1136/ejhpharm-2022-eahp.413","DOIUrl":null,"url":null,"abstract":"Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.","PeriodicalId":393937,"journal":{"name":"Section 7: Post Congress additions","volume":"119 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis\",\"authors\":\"J. Pedreira Bouzas, EM García Rebolledo, C. Puivecino Moreno, M. García Gil\",\"doi\":\"10.1136/ejhpharm-2022-eahp.413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.\",\"PeriodicalId\":393937,\"journal\":{\"name\":\"Section 7: Post Congress additions\",\"volume\":\"119 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Section 7: Post Congress additions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1136/ejhpharm-2022-eahp.413\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section 7: Post Congress additions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ejhpharm-2022-eahp.413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
4CPS-257 Effectiveness and safety of nintedanib and pirfenidone in patients with idiopathic pulmonary fibrosis
Background and importance Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a poor prognosis. Nintedanib and pirfenidone are the only drugs indicated for this path-ology. In pivotal clinical trials these drugs reduced the decline in forced vital capacity (FVC), which is consistent with a slowing of disease progression. and objectives Evaluation of the effectiveness and safety of nintedanib and pirfenidone in IPF in a second-level hospital.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
